<DOC>
	<DOCNO>NCT01199731</DOCNO>
	<brief_summary>This 48 week , phase 2b study 150 HIV-1 infected antiretroviral therapy experience adult subject consist dose-ranging evaluation GSK2248761 blind dose 100 mg 200 mg daily control arm open-label etravirine ( ETV ) 200 mg twice daily . The background ART three arm darunavir/ritonavir ( DRV/r ) 600 mg/100 mg twice daily plus raltegravir ( RAL ) 400 mg twice daily . Antiviral activity , safety , PK , development viral resistance evaluate .</brief_summary>
	<brief_title>Dose-finding Study GSK2248761 Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection</brief_title>
	<detailed_description>Study SGN113399 Phase 2b randomize , partially-blinded , multicenter , parallel-group , dose-ranging study conduct HIV-1 infect ART-experienced adult document NNRTI resistance . A minimum 150 subject randomize 1:1:1 one two GSK2248761 dos control regimen contain ETV ( 50 subject per group ) ; subject also receive darunavir/ritonavir raltegravir . The trial partially blind , i.e . subject receive GSK2248761 investigator blind dose receive . Subjects blind whether receive GSK2248761 ETV . Randomization stratify : - HIV-1 VL screening , &lt; 50,000 copies/mL &gt; /50,000 copies/mL , - Darunavir susceptibility ( screen phenotype fold change &lt; 7 &gt; /7 20 ) Background ART administer open-label . The primary endpoint analysis take place subject complete Week 16 . An optimal dose GSK2248761 determine Week 16 analysis ; dose selection confirm use analysis subject follow completion Week 24 . If clear efficacy , safety tolerability advantage drive dose selection GSK2248761 , subject receive non-selected dose GSK2248761 switch select dose follow dose confirmation , subject complete Week 24 . If differentiation dose make base objective measure efficacy , safety tolerability , dos continue Week 48 . After Week 48 , subject expect obtain local access commercially available ART . No regimen switch either background ART ( DRV/r RAL ) test agent control ( GSK2248761 ETV ) allow 48 week period study . Study Endpoints/Assessments Subjects assessment perform include baseline demographic , disease characteristic , pharmacogenetics ( PGx ) safety ( laboratory clinical evaluation ) . On study safety , efficacy , virologic , immunologic , PK evaluation also conduct . The primary endpoint proportion subject HIV-1 RNA &lt; 50copies/mL Week 16 . Dose selection base primarily antiviral activity tolerability conjunction immunologic , safety , virologic resistance PK measure . Data Week 24 analysis use confirm dose selection . ViiV Healthcare new sponsor study , GlaxoSmithKline process update system reflect change sponsorship</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>HIV1 infect adult great equal 18 year age . Females eligible enter participate study ( 1 ) nonchildbearing potential , ( 2 ) child bear potential negative pregnancy test screen Day 1 agrees use protocolspecified method birth control study . HIV1 infection screen plasma HIV1 RNA great equal 400copies/mL Previously receive current treatment antiretroviral therapy ( HAART ) HIV1 infection ( patient may ART time screen ) HIV1 harbor NNRTI resistance screen genotype ( define presence least 1 NNRTI resistanceassociated mutation ) Any preexist physical mental condition ( include substance abuse disorder ) , opinion Investigator , may interfere subject 's ability comply dose schedule and/or protocol evaluation may compromise safety subject Any condition , opinion Investigator , may interfere absorption , distribution , metabolism excretion drug render subject unable take oral medication Women currently breastfeed Any evidence active Centers Disease Prevention Control ( CDC ) Category C disease [ CDC , 1993 ] , except cutaneous Kaposi 's sarcoma require systemic therapy History ongoing clinically relevant hepatitis within previous 6 month , include chronic hepatitis B virus ( HBV ) infection ( HBsAg positive ) . Asymptomatic individual chronic hepatitis C virus ( HCV ) infection exclude , however Investigators must carefully assess therapy specific HCV infection require ; subject anticipate require therapy randomize portion study must exclude History liver cirrhosis without hepatitis viral coinfection Ongoing clinically relevant pancreatitis History follow cardiac disease : myocardial infarction , congestive heart failure , document hypertrophic cardiomyopathy , sustain ventricular tachycardia Personal know family history prolong QT syndrome History presence allergy intolerance study drug component , history drug allergy , opinion Principal Investigator , contraindicate participation . In addition , heparin use PK sample , subject history sensitivity heparin heparininduced thrombocytopenia enrol HIV1 genotype result follow excluded : ( 1 ) Any screen genotype virus show Y181 mutation combination NNRTI resistanceassociated mutation , ( 2 ) Any screen genotype virus show Y181I Y188L alone combination NNRTI resistanceassociated mutation HIV1 phenotype result follow excluded : ( 1 ) Any screen phenotype virus show etravirine fold change &gt; 10 , ( 2 ) Any screen phenotype virus show darunavir fold change &gt; 20 , ( 3 ) Any screen phenotype virus show raltegravir fold change &gt; 1.5 Any acute laboratory abnormality screening , , opinion Investigator , would preclude subject 's participation study investigational compound . Any verified Grade 4 laboratory abnormality screen would exclude subject study participation unless Investigator provide compel explanation laboratory result ( ) assent medical monitor Any follow laboratory value screen : ( 1 ) Creatinine clearance &lt; 50 mL/min via CockroftGault method , ( 2 ) Alanine aminotransferase ( ALT ) great equal 5 time ULN . Subjects ALT &gt; 2xULN &lt; 5xULN may participate study , opinion Investigator GSK medical monitor lab abnormality interfere study procedure compromise subject safety , ( 3 ) Alanine aminotransferase ( ALT ) great equal 3xULN bilirubin great equal 1.5xULN ( &gt; 35 % direct bilirubin Any clinically significant find screen electrocardiograph ( ECG ) , specifically ( single repeat allow determine eligibility ) : ( 1 ) Heart rate &lt; 45 &gt; 100bpm ( male ) , &lt; 50 &gt; 100bpm ( female ) ; Note : A heart rate 100 110 BPM rechecked within 30 minute verify eligibility , ( 2 ) QRS duration &gt; 120msec , ( 3 ) QTc interval &gt; 450msec , ( 4 ) Nonsustained ( great equal 3 consecutive beat ) sustain ventricular tachycardia , ( 5 ) Sinus pause &gt; 2.5 second , ( 6 ) 2nd degree ( Type II ) high AV ( Atrioventricular ) block , ( 7 ) Evidence WPW ( WolffParkinsonWhite ) syndrome ( ventricular preexcitation ) , ( 8 ) Pathologic Q wave ( define Q wave &gt; 40msec OR depth &gt; 0.4 mV , ( 9 ) Any abnormality opinion investigator would interfere safety subject Treatment follow agent within 28 day prior screen , anticipated need agent study : ( 1 ) radiation therapy cytotoxic chemotherapeutic agent , ( 2 ) immunomodulators ( systemic corticosteroid , interleukin , interferon ) ; Note : Subjects use shortterm ( &lt; 7 day ) steroid taper inhale corticosteroid eligible enrollment , ( 3 ) Any nonprotocolspecified agent document activity HIV1 vitro Treatment HIV1 immunotherapeutic vaccine within 90 day prior screen Receipt experimental drug and/or vaccine within 28 day 5 halflives , twice duration biological effect experimental drug vaccine , whichever longer , prior screen Immunization within 28 day prior first dose IP</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>raltegravir</keyword>
	<keyword>NNRTI</keyword>
	<keyword>ritonavir</keyword>
	<keyword>darunavir</keyword>
	<keyword>HIV</keyword>
	<keyword>GSK2248761</keyword>
	<keyword>antiretroviral</keyword>
	<keyword>HIV Infection</keyword>
	<keyword>HAART</keyword>
</DOC>